Health Tip, 2913 Flower Street, Los Angeles, CA (2026)

05/30/2026

Norovirus is circulating at high levels across the United States right now, and wastewater surveillance data shows concentrations climbing sharply in the Northeast and San Francisco Bay Area.

'At the national level, norovirus is still in the HIGH category due to high concentrations over the last 21 days.' — Amanda Bidwell, Scientific Program Manager, WastewaterSCAN

WastewaterSCAN, a joint surveillance program run by Stanford and Emory universities, has tracked norovirus signals from August 1 through May 7 of the current season.

Bidwell explained why wastewater data matters more than clinical reports for this particular virus: 'Monitoring norovirus in wastewater is very helpful for this highly contagious virus, as there is not a lot of clinical data to describe outbreaks because most people recover at home without seeing a healthcare professional.'

A newer norovirus variant is contributing to spread, though not because the virus itself became more aggressive.

'The newer variant isn't more contagious in and of itself. It can spread more easily because fewer people have partial immunity to it, so they will get sick and spread the virus.' — Dr. Scott Roberts, Associate Medical Director of Infection Prevention, Yale School of Medicine

Southern California hiking trails have also seen documented norovirus cases, linked by the Pacific Crest Trail Association to shared water sources and high-contact trail environments.

Dr. Linda Yancey, an infectious disease specialist at Memorial Hermann in Houston, pushed back against alarm over the California cases specifically: 'There really isn't anything unusual about this one in California. They just got unlucky.'

Dr. Aaron Glatt, Chief of Infectious Diseases at Mount Sinai South Nassau on Long Island, emphasized that standard hygiene measures remain the most effective defense — particularly rigorous handwashing with soap and water, since alcohol-based hand sanitizers are less effective against norovirus than against other pathogens.

Infectious disease specialists across the three institutions consistently point to surface disinfection with bleach-based products, thorough cooking of shellfish, and staying home for at least 48 hours after symptoms resolve as the core prevention steps.

This article is for informational purposes only and does not constitute medical advice; consult a healthcare professional if you or someone in your care experiences severe dehydration or prolonged symptoms.

WastewaterSCAN continues real-time tracking, and Northeast-region signals will determine whether the current high-level classification escalates further into late spring.

05/30/2026

Millions of women with hormone-positive breast cancer may never need chemotherapy—and a genomic test can now tell doctors exactly who those patients are.

'Optima addresses a longstanding challenge in breast cancer care: identifying who truly benefits from chemotherapy and who does not,' said Prof Rob Stein, Chief Investigator and Professor of Breast Oncology at University College London.

The Optima trial, a randomized international study, presented its findings at the American Society of Clinical Oncology annual meeting in Chicago.

The trial used a genomic test that reads tumour biology directly—moving treatment decisions away from traditional clinical features like tumour size or lymph node status alone.

Prof Stein confirmed that patients guided by the test 'can safely avoid chemotherapy without compromising their outcomes.'

For patients, the relief was immediate and visceral: one trial participant described learning she could skip chemotherapy as feeling 'like Christmas.'

Prof Iain MacPherson, Co-Chief Investigator and Professor of Breast Oncology at the University of Glasgow, called the findings 'robust, practice-changing evidence that we can safely reduce the use of chemotherapy for many patients with hormone-sensitive breast cancer.'

MacPherson noted the results 'mark an important and significant step toward more personalised treatment,' with tumour biology now driving decisions rather than blunt clinical criteria.

The physical toll of chemotherapy—fatigue, immune suppression, long-term organ damage—makes avoidance a clinically meaningful outcome, not merely a quality-of-life preference.

Prof Stein added that for health systems, the approach 'represents a more efficient and evidence-based use of resources,' pointing to downstream savings alongside patient benefit.

The study does not apply to all breast cancer types—its findings cover hormone-sensitive, or hormone-positive, breast cancer specifically, and patients should discuss their individual tumour profile with their oncologist before drawing conclusions about their own treatment plan.

Independent validation across broader populations and longer follow-up windows will determine how quickly this genomic approach enters standard clinical guidelines worldwide.

05/29/2026

A blood-based biological age marker can identify people with up to ten times the normal risk of developing dementia — and researchers at King's College London say that risk is not locked in.

'Dementia is not an inevitable consequence of aging. It can potentially be delayed or prevented by modifying risk factors, including biological aging.' — Dr. Julian Mutz

The study, published by the Alzheimer's Association, analyzed UK Biobank data to assess how a metabolomic aging marker called MileAge — derived from blood metabolites — correlates with dementia outcomes.

Researchers found that when MileAge, which measures how fast the body is aging at a cellular level, was combined with the APOE genetic risk factor, dementia risk climbed tenfold compared to individuals without either marker.

'While tenfold is a very large increase, it reflects the combination of a powerful genetic risk factor with an indicator of biological aging.' — Dr. Julian Mutz

MileAge showed particular strength in predicting vascular dementia, the second most common form of the disease.

'The biological aging marker, MileAge, was especially predictive of vascular dementia, the second most common form of dementia.' — Dr. Julian Mutz

The finding that separates this study from prior genetic research is the modifiable nature of metabolomic aging — unlike APOE status, biological age measured through blood metabolites responds to lifestyle and clinical intervention.

'The important point is that these two sources of risk are complementary, and unlike genetic risk, metabolomic aging is potentially modifiable through lifestyle or clinical intervention.' — Dr. Julian Mutz

Dr. Marc Siegel, Fox News senior medical analyst and independent commentator on the study, underscored the role of the APOE gene specifically in Alzheimer's risk.

'It emphasizes the role of the APOE gene in provoking dementia, especially Alzheimer's.' — Dr. Marc Siegel

Siegel also flagged a specific cardiovascular dimension to the risk: 'There's a 60% increased risk of vascular dementia when poor health is combined with this gene.' — Dr. Marc Siegel

The study does not establish which specific lifestyle interventions most effectively reduce MileAge scores, nor does it define the clinical threshold at which intervention becomes urgent — both questions the research team has not yet answered in published data.

No randomized clinical trial has tested whether lowering a patient's MileAge score through targeted intervention directly reduces their dementia incidence, which means the modifiability claim, while biologically supported, lacks direct human trial confirmation.

If future randomized trials confirm that metabolic age can be measurably reduced and that reduction translates to lower dementia rates, MileAge could become a standard screening tool in preventive cardiovascular and neurological care.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your health regimen.

05/29/2026

If you took antidepressants during pregnancy and worried for years that you harmed your child, a University of Hong Kong meta-analysis published in The Lancet has an answer backed by 25 million pregnancies: the risk was never the medication.

'Our findings do not provide strong evidence that prenatal antidepressant exposure causes neurodevelopmental disorders,' said Dr. Wing-Chung Chang, psychiatry professor and senior author of the study.

The research analyzed 37 studies covering more than 25 million pregnancies to examine links between prenatal antidepressant use and outcomes including autism and ADHD.

The signal that alarmed parents for a decade — a slightly elevated autism rate in children of mothers who took antidepressants — disappeared once researchers accounted for the mother's underlying depression itself.

'What the literature has shown us so far is that while there does, at face value, appear to be an association of slightly increased risk of autism in mothers who take antidepressant medications, when you control for the underlying depressive disorder that risk goes away,' said Dr. Kathryn Erickson-Ridout, senior psychiatrist and research scientist at Kaiser Permanente Division of Research.

Dr. Erickson-Ridout added that biological pathways disrupted in major depression overlap with those relevant to autism — pointing to shared genetic architecture, not drug exposure, as the common thread.

Brian K. Lee, professor of epidemiology and biostatistics at Drexel University, framed the finding in terms every patient can grasp: 'The mental health of your family tree is in some way statistically associated with your risk of autism.'

The 2015 Canadian study by epidemiologist Anick Berard had seeded widespread concern by reporting an association between prenatal antidepressant use and autism diagnoses, but it did not fully adjust for parental psychiatric history — a confounding variable this new analysis specifically targeted.

Dr. Katie Unverferth, reproductive psychiatrist and medical director of UCLA Maternal Mental Health Program, noted that untreated depression during pregnancy carries its own documented risks for both mother and child, making the decision to stop medication far from risk-free.

'Pregnancy is such an anxious time at baseline — this study just provides additional reassuring data,' said Dr. Unverferth.

Dr. Chang emphasized that the findings align with existing clinical guidelines, which generally support continuing antidepressant treatment during pregnancy when clinically indicated — a position this meta-analysis now reinforces with the largest pooled dataset on the question to date.

The study does not resolve every open question: researchers note that specific antidepressant classes, dosage levels, and trimester timing still warrant individual clinical evaluation.

Pregnant patients currently on antidepressants, or considering stopping them, should discuss this evidence directly with their prescribing clinician before making any changes to their regimen.

With 37 studies and 25 million pregnancies behind this finding, the next scientific pressure point shifts to understanding exactly which genetic variants link parental depression to neurodevelopmental outcomes in children.

05/29/2026

A daily fish oil capsule may do more than protect your heart — University of Pennsylvania researchers found it measurably reduces aggression in people across every age group, gender, and setting tested.

The team analyzed 28 randomized clinical trials involving 3,918 participants to assess whether omega-3 supplementation affects aggressive behavior.

Both reactive aggression — the hot-headed, impulsive kind — and proactive aggression — cold, calculated hostility — dropped with supplementation, though reactive aggression showed a slightly larger effect.

The results held across children and adults, males and females, and participants drawn from community populations as well as clinical and prison settings.

The authors stated there is now enough evidence to begin using omega-3 supplementation as a tool to reduce aggression.

Every dosage used across the 28 trials fell within FDA-approved safety thresholds, and omega-3 supplements are widely available at low cost — two factors the researchers identified as relevant to practical implementation.

Omega-3s already carry established evidence for cardiovascular and cognitive benefits; this meta-analysis adds a behavioral dimension to that profile.

The source material does not specify the biological mechanism linking omega-3 intake to aggression reduction, and no individual researchers were named in the published findings.

A meta-analysis pools existing trial data rather than generating new experimental conditions, which means variability in dosage, trial duration, and participant characteristics across the 28 studies limits the precision of any single recommended protocol.

The analysis does not establish which dosage level, supplement form, or supplementation duration produces the most consistent effect — questions that prospective trials will need to answer before clinical guidelines can be standardized.

Independent researchers have not yet weighed in publicly on the University of Pennsylvania findings, and peer review details were not specified in the source material.

If omega-3 supplementation clears further scrutiny as a behavioral intervention, it could be integrated alongside existing aggression-management approaches in schools, mental health programs, and correctional settings — populations that appeared consistently in the 28 trials reviewed.

This article does not constitute medical advice. Consult a qualified healthcare provider before starting any supplement regimen.

05/29/2026

Millions of people are swallowing a tablespoon of olive oil chased with lemon juice every morning — and the claims attached to that ritual range from fat loss to full-body detox.

Registered Dietitian Robin Barrie Kaiden, MS, RD, CDN, CSSD, defines the practice plainly: 'The olive oil and lemon shot is 1–2 tablespoons of extra virgin olive oil mixed with the juice of a fresh lemon.'

'There's no strong evidence that olive oil and lemon create a unique synergistic detoxifying effect together,' Kaiden states. 'Most of the proposed benefits come from the individual properties of each ingredient rather than a special interaction between the two.'

That distinction matters, because each ingredient does carry documented nutritional value on its own terms.

Dietitian Johannah Katz, MA, RD, of Consumer Health Digest notes: 'Extra virgin olive oil provides polyphenols and other bioactive compounds that have consistently been associated with cardiometabolic and anti-inflammatory benefits in research studies.'

Kaiden adds that healthy fats slow gastric emptying, which may indirectly support blood sugar balance: 'Some people feel more satisfied after consuming them, which may indirectly help with blood sugar balance and cravings throughout the morning.'

Bowel regularity improvements reported by some users likely reflect increased fat and hydration intake rather than any special formula: 'Some people notice mild improvements in bowel regularity or digestion simply because they're increasing healthy fat intake, hydration, or becoming more intentional about morning nutrition habits,' Kaiden explains.

The detox claims circulating on social media run hardest against established physiology: 'Your liver and kidneys already perform detoxification extremely efficiently when adequately nourished and hydrated,' Kaiden states. 'No single drink can replace those systems.'

Skin-glow claims have a partial nutritional basis — vitamin C supports collagen synthesis, and olive oil contains antioxidants — but Kaiden ties that benefit to a broader dietary pattern, not a single daily shot.

Adults considering this ritual should weigh that extra virgin olive oil delivers roughly 120 calories per tablespoon, a dosage that adds up if consumed daily alongside a calorie-controlled plan.

Anyone managing cardiovascular conditions, metabolic disorders, or acid reflux should speak with a physician before adding this to their routine, as lemon juice can aggravate reflux and high fat intake may require monitoring in certain clinical contexts.

The honest read: the individual ingredients carry real nutritional credentials, the viral packaging around them does not.

05/28/2026

Colorectal cancer now kills more Americans under 50 than any other cancer — in both men and women — and a new American Cancer Society recommendation is trying to close the gap between who should be screened and who actually gets screened.

'Forward thinking and reality-based,' said Dr. Ursina Teitelbaum, Professor of Gastrointestinal Oncology and Section Chief of GI Cancers at the University of Pennsylvania's Penn Medicine, describing the updated guidelines.

The American Cancer Society updated its colorectal cancer screening recommendations to include blood-based testing as an approved option, naming the Shield test as the first blood test to earn that designation.

The Shield test gives clinicians a new tool for patients who decline colonoscopy, stool-based tests, or other established screening methods — not a replacement for those methods, but an addition to the menu.

Dr. Scott Kopetz, a gastrointestinal medical oncologist at The University of Texas MD Anderson Cancer Center, drew a clear line on who the test is actually for.

'The blood-based screening does not perform as well for detection of pre-cancer as the other screening options and therefore should be reserved for individuals who will not complete other recommended screening,' said Dr. Kopetz.

'Importantly, patients who otherwise would be willing to be screened by colonoscopy, stool-based tests, or other recommended methods should not swap to the blood-based assays,' he added.

That distinction matters clinically: the Shield test can miss early-stage cancers and precancerous lesions at rates higher than colonoscopy or stool-based tests, making it a catch-more-people tool rather than a best-accuracy tool.

Dr. Teitelbaum framed the tradeoff directly, noting that blood-based testing 'may miss early-stage cancers and precancerous lesions,' but argued that 'perfect is the enemy of good, and these new guidelines acknowledge the need to broaden the capture of screening, particularly in younger, vulnerable populations.'

For health-conscious adults approaching or already past 45 — the current recommended screening age — the practical implication is straightforward: if a blood draw is the only test a patient will agree to complete, that blood draw is now a clinically recognized option rather than an informal workaround.

Caregivers helping reluctant family members navigate screening conversations now have a lower-barrier option to present, backed by a formal ACS recommendation rather than anecdotal reassurance.

Dr. Kopetz placed the Shield test inside a longer arc of innovation: 'This is the first blood-based test, but won't be the last, and the hope is that future tests will continue to reduce the barriers to access to effective screening and will have improved performance.'

'The technology will only improve from here,' he said.

Neither Dr. Teitelbaum nor Dr. Kopetz was involved in producing the ACS recommendations, making their assessments independent of the body that issued them.

The core open question — how much the Shield test expands real-world screening rates among younger adults who previously went unscreened — will depend on uptake data that does not yet exist.

05/28/2026

Adding one avocado to your daily meals could meaningfully lower your dietary glycemic load — without changing anything else about how you eat.

'Changing lifestyle habits, especially eating patterns, can be daunting. After adopting this simple change for the six-month period, participants who consumed avocados showed an impressive, significant reduction in dietary GL by nearly 14 points compared to the control group.' — Sujatha Rajaram, Professor of Nutrition, Loma Linda University School of Public Health

Researchers at Loma Linda University School of Public Health conducted a secondary analysis of the Habitual Diet and Avocado Trial (HAT), published in Current Developments in Nutrition, the journal of the American Society for Nutrition.

The randomized clinical trial enrolled more than 1,000 adults — 73% female, average age 50 — over a six-month period.

The intervention group ate one large avocado daily; the control group consumed no more than two avocados per month.

At the end of six months, the avocado group showed a nearly 14-point reduction in dietary glycemic load compared to the control group.

Dietary glycemic load measures the total blood sugar impact of everything a person eats — making it a key metabolic marker for type 2 diabetes risk, which affects tens of millions of U.S. adults.

One-third of a medium avocado delivers 6 grams of unsaturated fat, 3 grams of fiber, and zero grams of sugar per serving.

Rajaram described the finding as evidence that a single, sustainable food addition — rather than a full dietary overhaul — can produce measurable metabolic change.

The study carries an important limitation: funding came from the Avocado Nutrition Center, which introduces a potential conflict of interest that independent researchers would need to account for in follow-up work.

The participant pool skewed heavily female at 73%, which limits how broadly these findings apply across sexes and age groups.

No independent expert quotes were available in the source data for this analysis.

Loma Linda University researchers note the HAT trial represents one of the largest and longest randomized dietary studies on a single whole food, and its glycemic load findings open a clear path for clinical trials targeting at-risk metabolic populations.

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before making changes to your diet, especially if you are managing blood sugar, cardiovascular conditions, or BMI-related health concerns.

05/28/2026

$3.5 million just landed behind a wearable that sends low-level electrical currents into your brain while you sleep — and whether that investment reflects genuine clinical promise or outpaces the evidence matters for anyone tracking their rest with a device.

Sychedelic, a healthtech startup developing brain wearables for sleep and anxiety, closed a $3.5M seed round led by Cultadvisors LLP, TurboStart, and IdeaBaaz.

The company's technology combines three distinct inputs: transcranial Direct Current Stimulation (tDCS), binaural audio, and heart rate variability (HRV) biofeedback.

tDCS applies a weak electrical current — typically under 2 milliamps — through electrodes placed on the scalp to modulate neuronal activity in targeted brain regions.

Clinical research on tDCS for sleep disorders exists, but the evidence base remains early-stage: most published randomized trials involve small sample sizes and laboratory rather than real-world conditions.

HRV biofeedback has a stronger track record in cardiovascular and stress research, with multiple peer-reviewed studies linking it to reductions in self-reported anxiety and improved autonomic regulation.

Binaural audio — delivering slightly different frequencies to each ear to produce a perceived third tone — has shown modest effects on relaxation in some clinical trial settings, though effect sizes vary widely across studies.

Sychedelic's funding will go toward scaling manufacturing and expanding its AI-enabled wellness systems, according to the company's announcement.

No independent clinical trial data specific to Sychedelic's combined tDCS-binaural-HRV platform was disclosed in the funding announcement.

That gap matters: combining three modalities into a single consumer wearable introduces variables that no individual study on tDCS, HRV biofeedback, or binaural audio has tested together under randomized conditions.

The $3.5M round arrived in the same news cycle as two other healthtech seed rounds — Rosarium Health at $6M and Paralign Health at $3M — signaling active investor appetite for technology-enabled wellness infrastructure.

For health-conscious adults considering brain stimulation wearables, the honest picture is this: the component technologies carry peer-reviewed support at varying levels, but no FDA-cleared consumer tDCS sleep device has completed large-scale, independent randomized trials proving efficacy for chronic insomnia or clinical anxiety.

Anyone managing a diagnosed sleep disorder or anxiety condition should consult a physician before substituting or supplementing treatment with any wearable stimulation device.

Sychedelic's next milestone — publishing or citing clinical outcome data from its specific platform — will determine whether the science catches up to the seed capital.

05/28/2026

Melanie Miller, a 59-year-old retired teacher in Michigan, put it plainly: 'I don't gamble. But I may as well. This is gambling.'

Congress chose not to extend enhanced federal tax credits in late 2024, and marketplace premiums jumped sharply for millions of Americans in 2025 open enrollment.

That spike pushed consumers toward short-term policies, fixed-indemnity plans, and healthcare sharing ministries — products that cost less each month but cover far less when a claim arrives.

Amy Killelea, assistant research professor at Georgetown University Center on Health Insurance Reforms, delivered a blunt counter to the appeal of lower premiums: 'Humans have bodies that can fail them.'

Robert Godfrey, a 64-year-old hair salon owner in Florida who enrolled in one of these plans, acknowledged the risk directly: 'Thank God I'm healthy.'

Jade Ramsey, a consumer in Arizona, learned the limits of alternative coverage through a claim denial — a pattern Georgetown researchers flag as a defining feature of these products.

Fixed-indemnity plans pay a set dollar amount per medical event regardless of actual costs, leaving policyholders responsible for the gap between what the plan pays and what a hospital bills.

Healthcare sharing ministries operate outside standard insurance regulation entirely, meaning they carry no legal obligation to pay any claim.

Colorado insurance broker Samantha Albritton observed increased marketing of fixed-indemnity plans to consumers priced out of ACA-compliant coverage during 2025 enrollment.

Brian Blase, president of the Paragon Health Institute, defended consumer access to these products: 'People should be able to spend their own money financing healthcare the way that works best for them.'

CMS spokesperson Christopher Krepich framed the agency's position around 'access to affordable coverage options, strengthening competition, and reducing unnecessary regulatory burdens, while maintaining appropriate consumer protections.'

Kansas, Florida, California, and Massachusetts have each moved to regulate these alternative products differently, creating a patchwork of consumer protections that varies sharply by state.

Covered California flagged the enrollment shift as a direct consequence of the federal credit expiration, with the state's regulated marketplace competing against products that face no requirement to cover pre-existing conditions or cap out-of-pocket costs.

Zion HealthShare reported enrollment data through February 2025 showing demand growth — a signal that the alternative market absorbed consumers who could not absorb the new premium levels.

Whether Congress revisits the enhanced credit structure will determine how many of those consumers remain in alternative plans through the next open enrollment window.

05/27/2026

Three compounds in a single slice of watermelon may work together to support blood pressure and blood flow — and a 2025 narrative review suggests the fruit carries measurable cardioprotective effects.

'Watermelon is a great addition to an overall healthy dietary eating pattern because it provides potassium, lycopene, and citrulline, which synergistically can help support blood pressure and blood flow.' — Michelle Routhenstein, preventive cardiology dietitian at EntirelyNourished

The 2025 review, which built on earlier 2022 research linking watermelon to lower blood pressure and improved heart health, examined how the fruit's key compounds act together on the cardiovascular system.

Kristin Kirkpatrick, dietitian at Cleveland Clinic Department of Wellness and Preventive Medicine and president of KAK Consulting LLC, points to one specific pathway the evidence highlights.

'Watermelon's impact on blood vessel health appears to be beneficial to overall cardiovascular health. This may be based on compounds that impact nitric oxide production, impacting overall blood vessel health.' — Kristin Kirkpatrick

A standard reference serving in the aggregated research is 100 grams, roughly two-thirds of a cup — a modest portion that delivers all three active compounds in combination.

The significance lies in that combination: potassium, lycopene, and citrulline are not unique to watermelon individually, but the fruit delivers all three in a single, low-calorie source with a high water content.

Routhenstein is direct about where watermelon fits in a broader cardiovascular strategy: 'While watermelon is a heart-healthy addition, in order to truly reduce your risk of heart attacks and strokes, it needs to be included within a complete heart-healthy diet.' — Michelle Routhenstein

The 2025 review is a narrative review, not a randomized clinical trial, which means it synthesizes existing research rather than generating new controlled data on dosage or outcomes.

No specific percentages for blood pressure reduction, participant counts, or placebo-controlled trial results appear in the current body of aggregated evidence cited by either expert.

Independent confirmation through large-scale randomized trials would be needed before any clinical recommendation on watermelon as a cardiovascular intervention could be established.

*This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your diet for cardiovascular health management.*

As metabolic and dietary research continues to examine whole-food interventions, watermelon's three-compound profile gives researchers a concrete target for the next generation of controlled cardiovascular nutrition trials.

Health Tip

05/30/2026

05/30/2026

05/29/2026

05/29/2026

05/29/2026

05/29/2026

05/28/2026

05/28/2026

05/28/2026

05/28/2026

05/27/2026

Address

Telephone

Website

Alerts

Shortcuts

Featured

Share

Category